Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gilead

Dr Reddy's inks pact with Gilead for once-yearly HIV prevention drug lenacapavir

Dr Reddy's Laboratories and Gilead Sciences have signed a licensing agreement. This pact involves investigational once-yearly lenacapavir for HIV prevention. The agreement facilitates manufacturing and supply planning for 120 countries. This collaboration builds upon a previous pact for twice-yearly lenacapavir.

The Economic Times

PAHO and Gilead Partner to Bring Biannual HIV Prevention Shots to 14 Latin American Countries

PAHO and Gilead partner to bring twice-yearly lenacapavir HIV PrEP shots to 14 Latin American countries facing rising regional infection rates.

Latin Times

Early Remdesivir Tracked with About 25 Percent Lower Death Risk in Hospitalized Patients with Kidney Disease

A claims-based study of 27,000 hospitalized COVID patients links early remdesivir to lower 28-day death risk. Gilead helped conduct the research.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead Wins Approval for a Single HIV Tablet Aimed at Patients Taking Handfuls of Pills Each Day

FDA approved Bixlenvo, a once-daily tablet combining bictegravir and lenacapavir for virologically suppressed adults on complex HIV regimens.

Medical Daily

FDA Decision Due Thursday on a Two-Drug HIV Pill Designed to Simplify Complex Daily Regimens

The FDA faces an August 27 target date on Gilead's bictegravir and lenacapavir tablet for adults already virally suppressed on HIV therapy.

Medical Daily

Meet Serena Joy, 'The Handmaid's Tale' Villain Behind Olivia Rodrigo's Most Outspoken Song

Olivia Rodrigo's surprise single 'Serena Joy' critiques complicity and supports reproductive rights, drawing inspiration from Margaret Atwood's 'The Handmaid's Tale'. Proceeds benefit multiple reproductive health organisations.

International Business Times UK

Once-Weekly HIV Pill Held Viral Suppression as Well as Daily Treatment in Two Phase 3 Trials

Two phase 3 trials found that a weekly islatravir and lenacapavir tablet matched daily HIV therapy at 48 weeks. Here is what the data show.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

California Supreme Court Rules Gilead Had No Legal Duty to Bring a Newer HIV Drug to Market Sooner

California's high court rejected a duty-to-innovate claim from about 24,000 HIV patients. Here is what the ruling does and does not decide.

Medical Daily

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Barchart

The FDA Approves the First-Ever Hepatitis Delta Treatment: Here's Why Hepatitis B Patients Should Get Tested

FDA approved bulevirtide May 22, 2026 — the first-ever Hepatitis Delta treatment. About 80,000 Americans have HDV. Here's who should ask for testing and what the approval means.

Medical Daily

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

MarketBeat

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden

South Africa is rolling out lenacapavir, a twice-yearly injectable drug for HIV prevention that the president calls a turning point in a country with the world’s highest burden of HIV

The Independent UK

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate

MarketBeat

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks

Gilead Sciences has outperformed other healthcare stocks, and analysts remain highly optimistic about the stock’s outlook

Woman & Home

The Testaments season 1 ending explained: Mattea Conforti weighs in on how the ‘powerful’ teenage girls of Gilead are poised for rebellion

The actress weighs in on THAT kiss and all your burning questions about the incredible finale

MarketBeat

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

Inverse

Will There Be A 'Testaments' Season 2? Hulu's 'Handmaid's Tale' Spinoff Just Got Great News

'The Testaments' has been renewed for a second season on Hulu, taking the fight with Gilead in a fresh direction.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Compugen Q1 Earnings Call Highlights

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the

MarketBeat

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

MarketBeat

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe

TechRadar

What is the release date for The Testaments episode 7 on Hulu and Disney+?

Gilead is tightening its grip as Mayday's plans become clearer. But when does The Testaments episode 7 drop on Hulu and Disney+?

Cinemablend

The Legit Reason I Hope One Scene-Stealing Handmaid's Tale Character Pops Up In The Testaments

Bring back Naomi!

Cinemablend

The Testaments’ Ball Episode Was Chilling. But That Coming Out Scene Got Me In My Feels

A rare moment of hope in Gilead.

Marie Claire

The Best Margaret Atwood Books, Ranked—From 'The Handmaid's Tale' to 'Alias Grace'

The beloved, feminist author has many books worth reading, beyond her bestsellers set in Gilead.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.